Renal protection with calcium antagonists: the role of lercanidipine

References

• Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87.
   PubMed Web of Science ®Google Scholar
• Martínez-Castelao A, Górriz JL, Portolés JM, et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol 2011;12:53.
   PubMed Web of Science ®Google Scholar
• Buckalew VM Jr, Berg RL, Wang SR, et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996;28:811–21.
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–81.
   PubMed Web of Science ®Google Scholar
• García-Donaire JA, Segura J, Cerezo C, Ruilope LM. A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Press 2011;20:322–34.
   PubMed Web of Science ®Google Scholar
• Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med 2000;160:1585–94.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Diabetes and hypertension: what is new? Minerva Cardioangiol 2009;57:705–22.
   PubMedGoogle Scholar
• Fox CS, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380:1662–73.
   PubMed Web of Science ®Google Scholar
• Escobar C, Echarri R, Barrios V. Emerging drug combinations to optimize renovascular protection and blood pressure goals. Int J Nephrol Renovasc Dis 2012;5:69–80.
   PubMedGoogle Scholar
• Mallat SG. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc Diabetol 2012;11:32.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET® study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–53.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Homma K, Wakino S, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010;59:84–95.
   PubMedGoogle Scholar
• Egan CG, Pontremoli R. Role of the fixed-dose combination lercanidipine–enalapril in renal protection. J Nephrol 2011;24:428–37.
   PubMed Web of Science ®Google Scholar
• Agodoa LY, Appel L, Bakris GL, et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719–28.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, et al. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421–31.
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672–8.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, et al; ACCOMPLISH trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173–81.
   PubMed Web of Science ®Google Scholar
• Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936–46.
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004;17:259–66.
   PubMedGoogle Scholar
• Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;27:73–80.
   PubMed Web of Science ®Google Scholar
• Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin–angiotensin axis-blocking drugs. Ren Fail 2010;32:192–7.
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Leonardi A, Testa R, et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000;35:775–9.
   PubMed Web of Science ®Google Scholar
• Robles NR. Calcium antagonists and renal failure progression. Ren Fail 2008;30:247–55.
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Tomassoni D, Di Tullio MA, Amenta F. Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin Exp Hypertens 2002;24:727–40.
   PubMed Web of Science ®Google Scholar
• Martinez ML, Rizzi E, Castro MM, et al. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 2008;599:110–16.
   PubMed Web of Science ®Google Scholar
• Borghi C, Cicero AF. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril. Clin Drug Investig 2010;30:843–54.
   PubMed Web of Science ®Google Scholar
• Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer Adherence 2012;6:449–55.
   PubMed Web of Science ®Google Scholar